Context Therapeutics (CNTX) Assets (2020 - 2026)
Context Therapeutics (CNTX) posted Assets of $58.9 million for Q1 2026, down 14.07% sequentially from $68.5 million in Q4 2025, and down 36.69% YoY from $93.0 million in Q1 2025.
Context Therapeutics (CNTX) Assets (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Assets for 7 years, with the latest figure at $58.9 million in Q1 2026.
- Quarterly Assets fell 36.69% year-over-year to $58.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.9 million (down 36.69% YoY) and the FY2025 annual result came in at $68.5 million, down 30.2% from the prior year.
- Assets eased to $58.9 million in Q1 2026 per CNTX's latest filing, from $68.5 million in the prior quarter.
- Over five years, Assets peaked at $102.7 million in Q2 2024 and troughed at $11.1 million in Q1 2024.
- A 5-year average of $56.2 million and a median of $47.0 million in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2024: Assets surged 1762.65% in 2022, then slumped 65.43% in 2024.
- Over 5 years, Assets stood at $38.0 million in 2022, then tumbled by 57.69% to $16.1 million in 2023, then jumped by 510.9% to $98.1 million in 2024, then plunged by 30.2% to $68.5 million in 2025, then dropped by 14.07% to $58.9 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $58.9 million, $68.5 million, and $79.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Context Therapeutics | 49.23 Mn | 49.23 Mn | - | 46.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.13 Mn |
| Mar 31, 2026 | 58.86 Mn |
| Dec 31, 2025 | 68.49 Mn |
| Sep 30, 2025 | 79.23 Mn |
| Jun 30, 2025 | 87.15 Mn |
| Mar 31, 2025 | 92.97 Mn |
| Dec 31, 2024 | 98.13 Mn |
| Sep 30, 2024 | 86.33 Mn |
| Jun 30, 2024 | 102.71 Mn |
| Mar 31, 2024 | 11.05 Mn |
| Dec 31, 2023 | 16.06 Mn |
| Sep 30, 2023 | 22.99 Mn |
| Jun 30, 2023 | 27.76 Mn |
| Mar 31, 2023 | 31.97 Mn |
| Dec 31, 2022 | 37.97 Mn |
| Sep 30, 2022 | 42.08 Mn |
| Jun 30, 2022 | 44.70 Mn |
| Mar 31, 2022 | 47.03 Mn |
| Dec 31, 2021 | 51.31 Mn |
| Sep 30, 2021 | 2.26 Mn |